Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I.

"Declaration of Competing Interest This study was supported by a grant from Sanofi Corporation. Dr. Dickson is a listed inventor on Patent #USSN 15/946,505; 0WVR-223,143-US for enzyme replacement therapy for mucopolysaccharidosis IIID. Dr. Dickson also receives research support from M6P Therapeutics, Alnylam, and Mandos Health."

"Funding for this study was provided by Sanofi Corporation, the 10.13039/100013927National MPS Society, and the Lysosomal Disease Network. The Lysosomal Disease Network (LDN) U54-NS065768 is a part of the National Institute of Health (NIH) Rare Diseases Clinical Research Network, supported through collaboration between the NIH Office of Rare Diseases Research at the National Center for Advancing Translational Science, the National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding was also provided by the National Science Foundation (NSF) Graduate Research Fellowship Program DGE-1745038 and National Heart, Lung, and Blood Institute (NHLBI) F31 HL165903-01A1 to S. H. S.-h.K. was supported by a T32 fellowship in the UCLA Medical Genetics Training Program (GM008243). rhIDU in the form of laronidase was donated by Sanofi Corporation. Sarah C. Hurt: Formal analysis, Investigation, Writing – original draft, Writing – review & editing. Moin U. Vera: Conceptualization, Funding acquisition, Methodology, Writing – review & editing. Steven Q. Le: Investigation, Methodology, Writing – review & editing. Shih-hsin Kan: Investigation, Methodology, Writing – review & editing. Quang Bui: Investigation, Methodology. Patricia I. Dickson: Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – review & editing. This study was supported by a grant from Sanofi Corporation. Dr. Dickson is a listed inventor on Patent #USSN 15/946,505; 0WVR-223,143-US for enzyme replacement therapy for mucopolysaccharidosis IIID. Dr. Dickson also receives research support from M6P Therapeutics, Alnylam, and Mandos Health."